NZ777273B2 - Factor XI antibodies and methods of use - Google Patents
Factor XI antibodies and methods of useInfo
- Publication number
- NZ777273B2 NZ777273B2 NZ777273A NZ77727316A NZ777273B2 NZ 777273 B2 NZ777273 B2 NZ 777273B2 NZ 777273 A NZ777273 A NZ 777273A NZ 77727316 A NZ77727316 A NZ 77727316A NZ 777273 B2 NZ777273 B2 NZ 777273B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- variable region
- chain variable
- subject
- heavy chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Abstract
The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI ("Factor XIa"), and pharmaceutical compositions and methods of treatment comprising the same.
Claims (25)
1. Use of an antibody or antigen-binding fragment thereof in the manufacture of a medicament for the treatment of a thromboembolic disorder in a subject afflicted with or at risk of developing a thromboembolic disorder, wherein the antibody or n-binding fragment thereof is to be administered to the subject at a dose of at least 90 mg, and wherein the antibody or antigen-binding nt thereof comprises: i. a heavy chain variable region CDR1 of SEQ ID NO: 23; a heavy chain variable region CDR2 of SEQ ID NO: 24; a heavy chain variable region CDR3 of SEQ ID NO: 25; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 34; and a light chain le region CDR3 of SEQ ID NO: 35; ii. a heavy chain variable region CDR1 of SEQ ID NO: 26; a heavy chain variable region CDR2 of SEQ ID NO: 27; a heavy chain variable region CDR3 of SEQ ID NO: 28; a light chain variable region CDR1 of SEQ ID NO: 36; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 38; iii. a heavy chain variable region CDR1 of SEQ ID NO: 43; a heavy chain variable region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 45; a light chain variable region CDR1 of SEQ ID NO: 47; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 15; or iv. a heavy chain variable region CDR1 of SEQ ID NO: 46; a heavy chain variable region CDR2 of SEQ ID NO: 4; a heavy chain variable region CDR3 of SEQ ID NO: 5; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 14; and a light chain variable region CDR3 of SEQ ID NO: 15.
2. The use of claim 1, wherein: (i) the antibody or antigen-binding fragment thereof comprises a variable region heavy chain of SEQ ID NO: 9 and a variable region light chain ce of SEQ ID NO: (ii) the dy or antigen-binding nt thereof comprises a variable region heavy chain of SEQ ID NO: 29 and a variable region light chain sequence of SEQ ID NO: (iii) the antibody comprises a heavy chain sing the amino acid sequence of SEQ ID NO: 31 and a light chain comprising the amino acid sequence of SEQ ID NO: 41; (iv) the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 11 and a light chain comprising the amino acid sequence of SEQ ID NO: 21.
3. The use of claim 2, wherein the dy comprises D265A and P329A substitutions in the Fc domain.
4. The use of any one of claims 1-3, wherein the subject is afflicted with or at risk of developing a thromboembolic disorder ed from the group consisting of: venous thromboembolism, paroxysmal atrial fibrillation or atrial r, stroke associated with atrial fibrillation or atrial flutter, deep vein thrombosis (DVT), cancer, transient ischemic attack, severe protein S deficiency, thromboembolic stroke, ischemic stroke, systemic embolism, and myocardial infarction.
5. The use of any one of claims 1-4, wherein the subject is afflicted with one or more of stroke associated with atrial lation and deep vein thrombosis.
6. The use of any one of claims 1-5, wherein the subject is afflicted with stroke associated with atrial fibrillation or atrial flutter.
7. The use of claim 6, wherein the atrial fibrillation or atrial flutter is paroxysmal atrial fibrillation (PAF).
8. The use of any one of claims 1-4, wherein the subject is afflicted with or at risk of developing venous thromboembolism.
9. The use of any one of claims 1-5, n the subject is afflicted with or at risk of developing deep vein thrombosis (DVT).
10. The use of claim 8 or 9, the treatment further comprising measuring efficacy by incidence of DVT occurrence.
11. The use of any one of claims 1-10, wherein the subject is at high risk for bleeding.
12. The use of any one of claims 1-4 or 8-11, wherein the subject has undergone a medical procedure ed from the group ting of knee replacement surgery, hip replacement y, orthopedic surgery, ker installation, catheter installation, thoracic surgery, and abdominal surgery.
13. The use of claim 12, wherein the medical procedure is knee replacement surgery.
14. The use of any one of claims 1-7, wherein the subject at risk is ted with one or more of hypertension, congestive heart failure, left ventricular hypertrophy, and diabetes mellitus.
15. The use of any one of claims 1-14, the treatment further comprising evaluating efficacy of the antibody or antigen-binding fragment f by one or more biomarkers selected from the group consisting of free Factor XI, total Factor XI, Factor XI coagulation ty, ted l thromboplastin time, and D-dimer.
16. The use of any one of claims 1-15, the treatment further comprising evaluating adverse events to the antibody or n-binding fragment thereof by measuring bleeding events and/or the presence of rug antibodies.
17. The use of claim 16, the treatment further comprising applying one or more of the following to the t experiencing an adverse event, wherein the adverse event is a bleeding event: (i) fluid replacement using colloids, crystalloids, human plasma, or plasma proteins, such as albumin; (ii) transfusion with packed red blood or whole blood; or (iii) administration of fresh frozen plasma (FFP), prothrombin complex trates (PCC), or activated PCC (APCC), such as factor VIII inhibitor and/or recombinant activated factor VII.
18. The use of any one of claims 1-17, the treatment further comprising administration to the subject afflicted with or at risk of developing a thromboembolic disorder an effective amount of a statin therapy.
19. The use of any one of claims 1-18, wherein a dose of about 150 mg of the antibody or antigen-binding fragment thereof is to be administered to the subject.
20. The use of any one of claims 1-19, wherein the antibody or antigen-binding fragment thereof is to be stered to the subject subcutaneously or intravenously.
21. The use of any one of claims 1-20, wherein the antibody or antigen-binding fragment thereof is to be administered to the subject once a month.
22. The use of any one of claims 1-21, n the dy or antigen-binding fragment thereof is to be administered to the subject in a pharmaceutical composition further comprising sucrose, a polysorbate, L-histidine, and histidine HCl monohydrate.
23. The use of claim 22, wherein the pharmaceutical ition is at a pH of about 5.5.
24. The use of any one of claims 1-23, wherein the antibody or antigen-binding fragment thereof is an anti-Factor XI (FXI) and/or anti-activated Factor XI (FXIa) antibody or antigen-binding fragment thereof.
25. The use of claim 1, substantially as herein described with nce to any one of the examples and/or
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184955P | 2015-06-26 | 2015-06-26 | |
| US201662341568P | 2016-05-25 | 2016-05-25 | |
| NZ738480A NZ738480B2 (en) | 2016-06-24 | Factor xi antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ777273A NZ777273A (en) | 2025-05-30 |
| NZ777273B2 true NZ777273B2 (en) | 2025-09-02 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102176469B1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| CN111971062A (en) | Monoclonal antibody preparation for resisting human PD-1, combined medicament and application thereof | |
| US20060171946A1 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
| JP6224608B2 (en) | Anti-adrenomedullin (ADM) antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment of acute disease or condition in a patient to stabilize blood circulation | |
| JP6193871B2 (en) | Anti-adrenomedullin (ADM) antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold for preventing or reducing organ dysfunction or organ failure in patients suffering from chronic or acute diseases or conditions | |
| JP2017536414A5 (en) | ||
| BR112020000162A2 (en) | bispecific antibodies checkpoint inhibitors | |
| JP7114491B2 (en) | Anti-Mac-1 antibody | |
| EP2477653A1 (en) | Dosage regimen for administering an epcamxcd3 bispecific antibody | |
| RU2014145841A (en) | Therapeutic biological product for the treatment of hepatocellular carcinoma | |
| WO2016122996A1 (en) | Vegfa/ang2 compounds | |
| FI3463436T3 (en) | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| KR20250004928A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| BR112021008795A2 (en) | MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND THEIR USES | |
| WO2023240082A2 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| WO2023230078A1 (en) | Antibody biopharmaceutical formulations including polymer excipients | |
| FI3852617T3 (en) | Use of antibody fragments to reverse the activity of ticagrelor | |
| WO2016162867A1 (en) | Combination therapy of macrophage activating factor and pd-1 signaling inhibitors | |
| US10556953B2 (en) | Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction | |
| US20190330341A1 (en) | Use of cd47 antibodies | |
| KR102654035B1 (en) | Doppel-Inhibiting Agents | |
| NZ777273B2 (en) | Factor XI antibodies and methods of use | |
| EP1812797B1 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
| NZ777273A (en) | Factor xi antibodies and methods of use | |
| CN107406498A (en) | Immunoglobulin-like molecules targeting fibronectin‑EDA |